Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Forecast: What Market Value Is Expected By 2030?
The programmed death (PD)-1 non-small cell lung cancer market has experienced robust expansion in recent years. Projected to rise from $27.5 billion in 2025 to $29.92 billion in 2026, this growth reflects a compound annual growth rate (CAGR) of 8.8%. Several factors drove the historical period’s development, including the restricted number of PD-1 inhibitors approved for NSCLC, a rising prevalence of lung cancer, heightened physician awareness of immune checkpoint therapies, the continued reliance on chemotherapy as a standard treatment, and the early clinical trial achievements of pembrolizumab and nivolumab.
The market for programmed death (PD)-1 treatments in non-small cell lung cancer is projected to experience substantial growth over the coming years. By 2030, it is anticipated to reach a value of $41.45 billion, reflecting an 8.5% compound annual growth rate (CAGR). Growth during the forecast period is being driven by the emergence of novel combination therapies, the expansion of biomarker-guided personalized medicine, the increasing use of mRNA vaccine-based approaches, heightened investment in immuno-oncology research, and rising levels of public and private funding aimed at cancer immunotherapy. Key trends expected over this period include a greater reliance on PD-1 monotherapy for NSCLC, an uptick in combination regimens incorporating chemotherapy, CTLA-4 inhibitors, and VEGF inhibitors, increased funding for targeted therapy and mRNA vaccine development, a broadening of both first-line and second-line treatment choices, and the integration of personalized medicine along with biomarker testing into therapeutic planning.
Download A Free Sample Report For Comprehensive Market Insights:
Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Industry Drivers: What Is Driving Revenue Growth?
The market for programmed death (PD)-1 non-small cell lung cancer is being propelled forward by the growing uptake of personalized treatment approaches. These therapies involve medical strategies specifically designed around an individual’s genetic makeup, lifestyle factors, and unique disease traits to deliver more precise and successful results. The heightened demand for such personalized care is driven by the expanding use of genomic profiling and biomarker testing, which enable clinicians to pinpoint specific genetic mutations and biological indicators, thereby choosing treatments that are better suited to each patient. In the context of PD-1 non-small cell lung cancer (NSCLC), personalized treatments optimize therapy selection by considering a patient’s genetic profile, tumor attributes, and immune function. A notable example occurred in February 2024, when the Personalized Medicine Coalition, a US-based nonprofit, reported that the FDA had approved 16 new personalized treatments for rare diseases in 2023, compared to only six in 2022. Consequently, the rising adoption of these individualized therapies is fueling expansion in the PD-1 NSCLC market.
Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Segmentation Trends And Revenue Drivers
The programmed death (pd)-1 non-small cell lung cancer market covered in this report is segmented –
1) By Drug Type: Monotherapy, Combination Therapy
2) By Line of Therapy: First-line Treatment, Second-line And Beyond
3) By End User: Hospitals, Specialty Cancer Centers, Academic And Research Institutes, Other End Users
Subsegments:
1) By Monotherapy: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Toripalimab, Tislelizumab, Camrelizumab, Dostarlimab, Other Monotherapy Drug Types
2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy, Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor, Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor, Programmed Death (PD)-1 Inhibitor And Targeted Therapy, Programmed Death (PD)-1 Inhibitor And Radiation Therapy, Triple Combination Therapy, Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine, Other Combination Drug Types
Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Growth Trends: What Is Influencing The Future Outlook?
Key players in the programmed death (PD)-1 non-small cell lung cancer market are concentrating on conducting clinical trials for cutting-edge therapies, including monotherapy, to enhance patient outcomes. Monotherapy refers to a treatment method where only one drug or therapeutic approach is used to manage a particular disease or condition. For example, in March 2025, Akeso, Inc., a biopharmaceutical firm based in China, reported favorable findings from its Phase III HARMONi-2 trial, which tested Ivonescimab (AK112) combined with chemotherapy as a first-line therapy for advanced non-small cell lung cancer (NSCLC). The study successfully achieved its primary goal by notably prolonging progression-free survival relative to pembrolizumab, underscoring the effectiveness of this dual-targeted bispecific antibody.
Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Industry Leaders: Which Organizations Are Driving Competition?
Major companies operating in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc.
Access The Complete Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report:
Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Regional Analysis And Leading Geography
North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the programmed death (pd)-1 non-small cell lung cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model